1. Home
  2. ALVO vs AVLN Comparison

ALVO vs AVLN Comparison

Compare ALVO & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alvotech

ALVO

Alvotech

HOLD

Current Price

$3.46

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$28.98

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALVO
AVLN
Founded
2013
N/A
Country
Luxembourg
United States
Employees
1460
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
ALVO
AVLN
Price
$3.46
$28.98
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
1.1M
590.5K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.28
N/A
Revenue Next Year
$18.63
N/A
P/E Ratio
$18.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$27.42
52 Week High
$9.94
$33.32

Technical Indicators

Market Signals
Indicator
ALVO
AVLN
Relative Strength Index (RSI) 44.26 30.27
Support Level $3.09 $27.42
Resistance Level $3.83 $33.32
Average True Range (ATR) 0.23 2.86
MACD -0.05 -0.35
Stochastic Oscillator 5.06 7.11

Price Performance

Historical Comparison
ALVO
AVLN

About ALVO Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: